SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH H impact

REGN: FDA, EMA Accept Cemdisiran Apps

Regeneron Pharmaceuticals announces FDA and EMA acceptance of regulatory applications for cemdisiran to treat generalized myasthenia gravis

REGN

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.